Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors.

Next Previous
Trial Profile

A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabrafenib (Primary) ; Midazolam
  • Indications Brain metastases; Colorectal cancer; Gastrointestinal stromal tumours; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 06 Apr 2012 Actual patient number 184 added as reported by ClinicalTrials.gov.
  • 06 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 02 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top